Discover our magazine on the new Jules Bordet Institute
The Jules Bordet Institute is publishing a magazine on its plans to move to a brand new building.
The Jules Bordet Institute is publishing a magazine on its plans to move to a brand new building.
This very latest radiotherapy equipment combines the benefits of a linear particle accelerator and the precision of an MRI system.
To evaluate a new strategy for breast cancer screening, based on the individual risk of each woman.
The Jules Bordet Institute supports the international Movember campaign that every year alerts public opinion to male cancers
The Jules Bordet Institute, reference centre in the fight against cancer, is supporting Nutrition Day 2021.
12 and 13/12/2021 : The Christmas Market is coming to the New Jules Bordet Institute!
Le Conseil d’administration de l’H.U.B a désigné Renaud Witmeur et le Professeur Jean-Michel Hougardy respectivement comme Directeur Général et Directeur Général Médical de l’Hôpital Universitaire de Bruxelles (H.U.B).
The new Jules Bordet Institute presents its best wishes for 2022!
25 patients at the Jules Bordet Institute accompanied by care staff will be taking competing in the Brussels 20 km.
The Jules Bordet Institute Hematology Department honoured with PAtient CEntricity Award from the Belgian Hematology Society (05/02/2022)
DECRESCENDO, a new large clinical trial to test a less intensive chemotherapy treatment for patients with HER2+ breast cancer
Department :
Intensive care unit
02/555.44.45
Department :
Intensive care unit
02/555.44.45
Department :
Internal medicine
, Cardiology
A new era in treating and diagnosing patients in Nuclear Medicine
Le 12 mai 2022, Journée internationale des infirmières et infirmiers
Ce 29/5, sur la ligne de départ des 20 km de Bruxelles, parmi la foule de coureurs, se trouvait une équipe hors du commun : Impulsion by Bordet
The Psycho-Oncology Clinic is pleased to announce the reopening of its reception area on Wednesday afternoons
Do you want to contribute to research to combat the Coronavirus (COVID-19) among cancer patients?
This technology will make possible to refine our knowledge of the heterogeneity of tumours and of the tumour microenvironment.